Tolerability and effectiveness of glucagon-like peptide-1 receptor agonists in patients with inflammatory bowel disease
By contrast, treatment of high-risk diabetic patients with GLP-1R agonists such as lixisenatide and exenatide, which are based on the structure of nonhuman exendin 4, has not resulted in consistent reductions in MACEs (17, 18)
In the following years long acting, once weekly injected GLP-1 receptor agonists were approved (once-weekly exenatide, dulaglutide, albiglutide, semaglutide)
This maximizes the total usable life of their supply and ensures every dose comes from a fresh or recently-mixed vial
Look into alternative weight loss medications
Effects of liraglutide on expressions of lipid metabolism-related genes in rats with T2DM and fatty liver